πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 2,465 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 9650648

Methods and compositions for treatment of a genetic condition

Sangamo Biosciences, Inc. Β· Granted Tue May 16 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 11 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9650607

Modalities for the treatment of degenerative diseases of the retina

Astellas Institute for Regenerative Medicine Β· Granted Tue May 16 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 11 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9650417

Treatments for gastrointestinal disorders

IRONWOOD PHARMACEUTICALS, INC. Β· Granted Tue May 16 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 11 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9650352

Use of (2R, 6R)-hydroxynorketamine, (S)-dehydronorketamine and other stereoisomeric dehydr

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue May 16 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 11 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9649358

Methods for use of neural stem cell compositions for treatment of central nervous system l

The Regents of the University of California Β· Granted Tue May 16 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 11 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9649327

Composition of novel carbohydrate drug for treatment of human diseases

GALECTIN THERAPEUTICS, INC. Β· Granted Tue May 16 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 11 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9649320

Non-hormonal steroid modulators of NF-ΞΊB for treatment of disease

ReveraGen BioPharma, Inc. Β· Granted Tue May 16 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 11 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9649291

Treatment for obesity

Jazz Pharmaceuticals International III Limited Β· Granted Tue May 16 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 11 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9644216

Adeno-associated virus vectors for treatment of glycogen storage disease

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue May 09 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 04 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9642898

Use of serine protease inhibitors in the treatment of neutropenia

MED DISCOVERY S.A. Β· Granted Tue May 09 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 04 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9624306

Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of sa

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Apr 18 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 13 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9617305

Treatments for gastrointestinal disorders

IRONWOOD PHARMACEUTICALS, INC. Β· Granted Tue Apr 11 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 06 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9616047

Inhibitors of beta-catenin in treatment of colorectal cancer

Regents of the University of Minnesota Β· Granted Tue Apr 11 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 06 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9611230

1,3,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the tre

PTC THERAPEUTICS, INC. Β· Granted Tue Apr 04 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 30 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9603820

Ornithine aminotransferase inhibition with GABA analogues for treatment of hepatocellular

Northwestern University Β· Granted Tue Mar 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9603806

Pharmaceutical compositions for the treatment of Helicobacter pylori

RedHill Biopharma Ltd. Β· Granted Tue Mar 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9603796

Controlled release antimicrobial compositions and methods for the treatment of otic disord

The Regents of the University of California Β· Granted Tue Mar 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9597336

Therapy for treatment of chronic degenerative brain diseases and nervous system injury

The Regents of the University of California Β· Granted Tue Mar 21 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 16 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9597302

Combination of dofetilide and mexiletine for the prevention and treatment of atrial fibril

Heart Rhythm Solutions, Inc. Β· Granted Tue Mar 21 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 16 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9593108

Compounds and methods for antiviral treatment

PTC THERAPEUTICS, INC. Β· Granted Tue Mar 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9593069

Cyclohexane-1,3-diones for use in the treatment of amyotrophic lateral sclerosis

Northwestern University Β· Granted Tue Mar 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9586930

1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative di

Takeda Pharmaceutical Company Limited Β· Granted Tue Mar 07 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9585935

Intranasal oxytocin treatment to improve schizophrenia

The Regents of the University of California Β· Granted Tue Mar 07 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9585878

Treatment of BDNF-related disorders using laquinimod

TEVA PHARMACEUTICAL INDUSTRIES, LTD. Β· Granted Tue Mar 07 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted